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ABSTRACT 
 Neutron capture therapy with a new boron-porphyrin compound 
was tested in  a rat brain tumor model .  Although the concentration of 
boron in the tumor was too low to elicit a therapeutic effect, prominent 
histopathologic changes, such as necrosis, congestion and bleeding were 
observed in the tumors of the rats administered  the boron neutron capture 
therapy.   
 
INTRODUCTION 
 Tumor-selective uptake of boron is essential for effective boron 
neutron capture therapy (BNCT).  Borocaptate sodium(BSH) is one of the 
boron compounds used in BNCT[1], and favorable clinical results using 
BSH have been reported[2]. To increase the selectivity of tumor uptake of 
the boron compound, a new type of boron compound composed of BSH 
and metalloporphyrin has been developed.  This report describes the 
results of the treatment of rat brain tumors with  BNCT using the 
BSH-porphyrin compound STA-BX900. 
 
MATERIALS AND METHODS  
Boron compound 
  STA-BX900 consists of BSH and metalloporphyrin, which tends 
to be uptaken by malignant tumors [3].  STA-BX900 is  
2-dodecaboranyl thioethylcarbamoylmethyl-4-vinyl -deuteropophinato 
manganese(III).  Because STA-BX900 contains manganese within the 
porphyrin cage, it is not photoreactive.  The pharmacokinetic study of 
STA-BX900 revealed that this compound does not enter the normal brain 
tissue, and that a high tumor to blood ratio can be achieved 6 hours after 
intravenous injection of the compound [4].  Although the toxicity of 
STA-BX900 should be examined,  there was no clinical side effect of 
STA-BX900 for rats in this experiment.  STA-BX900 contains 12 boron 
atoms and the molecular weight of STA-BX900 is 917.8 gm/mol.  Boron 
accounts for 13% of the weight of the compound .   
Rat brain tumor model 
 9L gliosarcoma cells suspended in conditioned medium at a 
concentration of 1x104 cells per 10 ml were stereotactically implanted 
5mm deep in the right frontal lobe of Fisher 344 rats under pentobarbital 
anesthesia.  Magnetic resonance imaging (MRI) was performed 10 days 
after tumor cells were  implanted and those rats which did not develop 
brain tumors were excluded from the study.  Thirty-six rats were 
confirmed to have developed brain tumors using MRI with  
Gadopentetate Dimeglumine (Gd-DTPA).   
Experimental Therapy  
 All rats were transported to the Research Reactor Institute of Kyoto 
University (KUR).  The rats were divided into three groups of 12 rats 
each.  The control group received no radiation.  The neutron group 
received only neutron radiation to the head without the previous injection 
of  STA-BX900.  The therapy group received neutron radiation directed 
to the  head 6 hours after the intravenous injection of STA-BX900 
solution.  The injected dose was 0.05 mmol/kg.  The calculated neutron 
flux at the center of the radiation port was 3 x 109n/cm2/sec.  The neutron 
radiation time was 30 min.   The thermal neutron fluence of each rat was 
measured by mean of gold foil attached to the head of each rat.  The 
gamma dose was measured with a thermal luminescence dosimeter(TLD) 
attached to the head of each rat. 
Radiation dose 
 The calculated tumor dose of a 10B(n,α) reaction was 0.789 Gy 
under conditions where a tumor dose of 10B was  1 ppm.  The mean 
neutron fluence in the neutron group was 7.94+1.07 x 1012n/cm2.  One 
extreme value of neutron fluence in this neutron group was abandoned with 
the Smirnov test.  The mean neutron fluence in the therapy group was 
8.91+ 0.61x 1012n/cm2   showing no statistically significant difference 
with the neutron group (Student's t test).  The mean gamma dose in the 
neutron group was 3.91+ 0.33Gy.  One extreme value  of gamma dose in 
this group was abandoned with Smirnov test. The mean gamma dose in the 
therapy group was 4.29+0.44Gy. The difference between the two groups 
was not statistically significant (Student's t test). 
Survival and histopathological study 
 The survival times after the treatment were recorded and after death  
the brains were immediately removed and fixed in  formaldehyde solution.  
Coronal sections were performed through the center of the tumor and the 
diameter of the tumor and maximal cross-sectional area were measured. 
The tumor specimens were embedded in paraffin, sectioned and stained 
with hematoxylin and eosin.    The extent of the tumor invasion in 
surrounding tissues was graded as 1: none, 2: minimum, 3: moderate, 4: 
extensive.   Each specimen was microscopically evaluated for the 
presence or absence of mass effect of the tumor on normal brain tissue, 
subarachnoidal seeding of tumor cell, hydrocephalus or ventricular 
dilatation, intracerebral or intratumoral bleeding, intravascular congestion 
and necrosis of the tumor.   
 The survival times after the treatment were analyzed with Student's 
t test,  the Cox-Mantel test and the Wilcoxon test of Kaplan-Meier 
survival curves.  The maximal cross-sectional area of the brain tumor was 
analyzed with Student's t test.  Each histopathological parameter was 
analyzed with Chi square test. 
 
RESULTS      
Survival and tumor size 
 Mean survival time was 12.8+2.7 days for the control group, 
14.8+2.4 days for the neutron group and 16.2+4.4 days for the therapy 
group(Table 1).  The difference was statistically significant between the 
control and the therapy groups (p<0.05, Student's t test).  The analysis of 
survival curves obtained by the Kaplan-Meier method showed the 
statistically significant difference between the survival of the control and 
that of the neutron group by the Cox-Mantel test (p<0.05) but not by the 
Wilcoxon test <<Fig. 1>>.  The difference between the survival of the 
control group and the therapy group was statistically significant  by both 
the Cox-Mantel test (p<0.01) and the Wilcoxon test (p<0.05).   No 
statistically significant difference was observed between the neutron group 
and the therapy group with either the Cox-Mantel test or the Wilcoxon test.  
 The maximal cross-sectional area of the brain tumor at autopsy was 
43.9+16.5 mm2 for the control group, 39.0+23.4 mm2 for the neutron group 
and 36.4+22.0 mm2 for the therapy group.  The size of the tumor tended 
to decrease with therapy, but the difference among the three groups was not 
statistically significant.   
Histopathologic study 
 Twelve specimen per each group were evaluated.  The numbers of 
cases with bleeding for the control, neutron, and therapy groups were 1, 2, 
and 4, respectively <<Fig. 2, Table 2>>.  The numbers of cases with 
congestion in the tumor for the control, neutron, and therapy groups were 3, 
6, and 11, respectively.  The difference between the control and the 
therapy group was significant (p<0.01, Chi square test).   The difference 
between the neutron-treated and therapy group was also significant (p<0.05, 
Chi square test).  The numbers of cases with necrosis in the tumor for the 
control, neutron, and therapy groups were 3, 2, and 10, respectively.  The 
differences between the therapy and the control or the neutron groups were 
significant (p<0.01, Chi square test).  Figure 3 is a photomicrograph of 
the typical tumor in a control rat, showing the dense tumor tissue of the 9L 
gliosarcoma.   Figure 4 is a photomicrograph of the typical tumor in a rat 
from the therapy group, showing congestion, hemorrhage,  and necrosis 
of the tumor. 
 The mean scores for tumor extension for the control, 
neutron-treated and  therapy groups were 3.4+0.7, 2.5+1.1, and 3.3+0.9, 
respectively (Table 2).  The numbers of cases with mass effect for the 
control, neutron, and therapy groups were 11, 8, and 10, respectively.  
The numbers of cases with seeding of tumor cells for the control, neutron, 
and therapy groups were 10, 6, and 9, respectively.  The numbers of cases 
with hydrocephalus for the control, neutron, and therapy groups were 3, 1, 
and 3, respectively.   No statistically significant difference were  found 
in tumor extension, mass effect, seeding and hydrocephalus between each 
study groups.  
 
DISCUSSION 
 Malignant brain tumors are some of the most therapy-resistant 
tumors in spite of multimodality therapeutic trials[5].  BNCT is a bimodal 
radiotherapy that consists of tumor-selective uptake of boron compound 
and sufficient neutron radiation.  The thermal neutron is less destructive 
for normal brain tissue than for tissue which contains boron compound.  
Tumor cells which take up the boron compound sustain lethal damage due 
to the neutron capture B(n,a) reaction.  Each tumor cell invading the 
normal brain tissue would also be damaged, so this therapy is ideal for 
treating infiltrative glial tumors [6]. 
Tumor-selective uptake of the boron compound is essential for effective 
BNCT.  BSH does not enter normal brain tissue, however the high blood 
concentration relative to the tumor concentration is one of the limiting 
factors of BSH [7,8].  A high blood concentration of boron during BNCT 
leads to endothelial damage and subsequent radiation necrosis.  In order 
to achieve a high tumor/blood ratio of boron we developed the new 
compound STA-BX900.   In other studies, the pharmacokinetic 
parameters of this compound were measured using a relatively large size 
rat brain tumor model .  STA-BX900 demonstrated a high uptake by brain 
tumor cells and minimal uptake by normal brain cells[4].  In the study 
relative high tumor/blood ratio could be achieved compared with BSH.  
The concentration of boron in brain tumor cells in our previous study was 
approximately 1 ppm 6 hours after the injection of STA-BX900.  The size 
of the tumor  in the present experiment was smaller than that of the tumor 
in the pharmacokinetic study.  Small tumors tend to uptake more boron 
[9], so the concentration of boron in tumor would be higher in the present 
experiment. 
 The calculated surface dose of a 10B(n,a) reaction was 0.8 Gy.  
The total surface dose of the neutron group was the sum of 17O(n,a) and 
14N(n,p) reactions and the contaminated g dose, which was calculated as 
6.0Gy.  The total surface dose of the therapy group was the sum of  
10B(n,a), 17O(n,a) and 14N(n,p) reactions and the contaminated g dose, 
which was calculated as 7.2 Gy. 
 Despite the small difference in radiation dose between the neutron 
and the therapy group, the histopathological findings in these groups were 
remarkably different.  The therapy group demonstrated frequent necrosis, 
venous congestion and hemorrhage which suggest a disturbance of blood 
circulation in the tumor.  Hemorrhage may be caused by endothelial 
damage due  to BNCT.  Radiation necrosis normally occurs  some  
months after the radiation therapy[10].  Because the mean survival in our 
study was less than 28 days, we may assume that  the disturbance in blood 
circulation in our tumor model was not caused by usual radiation necrosis 
or fibrinoid necrosis of cerebral vessels.  Histopathologic examination of 
our tumor model after the BNCT did not demonstrate any pathologic 
change such as fibrinoid necrosis.  Goodman et al. reported progressive 
edema and necrosis in the peritumoral region after BNCT in a rat glioma 
model, although the concentration of boron in tumor was too low to obtain 
a lethal B(n,a) reaction [11].  They concluded that this histologic change 
indicated a pathologic endothelial response.  However in their model, 
bleeding, congestion or necrosis were not as frequently seen as in our 
present study.  These findings indicate that STA-BX900 may induce more 
damage to the endothelium than BSH.  This may be due to the difference 
in the intracellular distribution of  boron  which has to be further 
investigated.  In  future studies we will investigate the long-term 
pathophysiologic processes of the brain tumor and blood vessels after 
BNCT. 
 The pharmacokinetics of other boron porphyrin derivative such as 
BOPP have been investigated [12,13].   BOPP reached high 
concentration levels of boron in tumor tissue and the tumor-to-blood ratio 
was high.  However this compound induces some degree of clinical 
toxicity and is photoreactive [14], and in vitro it is more toxic to 9L 
gliosarcoma cell lines than BSH or BPA[15] .  These problems should be 
solved in the future. STA-BX900 is not photoreactive, but it clinical 
toxicity was not been evaluated as yet.      
 The results of the study demonstrated that survival time tended to 
increase and the size of the tumor to decrease after BNCT using this 
boron-porphyrin compound, although the concentration of boron in the 
tumor was too low to elicit a  therapeutic effect. Future pharmacologic 
improvement in STA-BX900 may involve increasing the content of boron 
in the molecule.  Moreover the improvement in the dose application 
should be considered to attain a more significant therapeutic effect.   
 
CONCLUSION 
 A neutron capture therapy experiment using a rat brain tumor 
model with a  boron-porphyrin compound is reported.  Prominent 
histopathologic changes such as  congestion, necrosis and hemorrhage, 
were observed in the tumors of the therapy group.  These findings would 
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Figure legends 
Fig. 1 Kaplan-Meier survival curve of control, neutron and therapy group 
rats  
Fig. 2 Number of rats with intratumoral bleeding, congestion, and necrosis. 
Fig. 3 Photomicrograph of the typical tumor in a control rat, showing the 
dense tumor tissue of the 9L gliosarcoma. 
Fig. 4  Photomicrograph of the typical tumor in a rat from the therapy 




Table I  Mean survival time and maximal cross-sectional area of each 
group of rats 
  Mean survival time (days) Max cross area (mm2) 
Control 12.8+2.7 *      43.9+16.5  
Neutron 14.8+2.4      39.0+23.4 
Therapy 16.2+4.4 *   36.4+22.0               
 
* The difference between control and therapy is statistically significant  
(p<0.05, Student 's t test). 
 
 
Table II  Histopathologic findings of each group of rats 
 
     control neutron therapy          
tumor extension 3.4+0.7 2.5+1.1 3.3+0.9 
Mass effect  11  8  10 
seeding   10  6  9 
hydrocephalus  3  1  3 
bleeding  1  2  4 
congestion  3 *  6 #  11*# 
necrosis  3*  2*  10*         
 
* The difference of number of rats with congestion between control and 
therapy and the difference of number of rats with necrosis between 
therapy and control or neutron are statistically significant (p<0.01, Chi 
square test). 
# The difference of number of rats with necrosis within tumor between 
neutron and therapy is statistically significant (p<0.05, Chi square test). 
